Get the Stockscreener App
3.02
7.86%
+0.22
After Hours:
3.25
0.23
+7.62%
Eledon Pharmaceuticals Inc stock is currently priced at $3.02, with a 24-hour trading volume of 611.09K.
It has seen a +7.86% increased in the last 24 hours and a +92.36% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.75 pivot point. If it approaches the $3.19 resistance level, significant changes may occur.
Previous Close:
$2.80
Open:
$2.83
24h Volume:
611.09K
Market Cap:
$114.53M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-0.5059
EPS:
-5.97
Net Cash Flow:
$-39.53M
1W Performance:
+30.74%
1M Performance:
+92.36%
6M Performance:
+137.80%
1Y Performance:
+34.22%
1D Range:
$2.83
$3.2884
52W Range:
$1.07
$3.2884
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949 238 8090
Address
19900 MacArthur Boulevard, Suite 550, Irvine
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Midday Stock Roundup: Eledon, Avid Bioservices Up - Orange County Business Journal
Orange County Business Journal
Eledon Pharmaceuticals Inc (ELDN) Stock: A Year of Decreases and Increases - The InvestChronicle
The InvestChronicle
Midday Stock Roundup: Eledon Pharma Shares Double - Orange County Business Journal
Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade - Zacks Investment Research
Zacks Investment Research
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Canada Finance
Yahoo Canada Finance
BVF Partners L.P. invests $5,931 in Eledon Pharmaceuticals pre-funded warrants By Investing.com - Investing.com
Investing.com
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Eledon Pharmaceuticals Inc (ELDN) Net Income 2024
ELDN net income (TTM) was -$40.33 million for the quarter ending December 31, 2023, a +54.16% increase year-over-year.
Eledon Pharmaceuticals Inc (ELDN) Cash Flow 2024
ELDN recorded a free cash flow (TTM) of -$39.53 million for the quarter ending December 31, 2023, a -39.06% decrease year-over-year.
Eledon Pharmaceuticals Inc (ELDN) Earnings per Share 2024
ELDN earnings per share (TTM) was -$1.79 for the quarter ending December 31, 2023, a +70.94% growth year-over-year.
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
0.77%
1.20%
Cap:
|
Volume (24h):